Felsenrose PhNT
When tradition meets science
The project focuses on the development of a standardized plant extract derived from Mediterranean species with historically documented use in neurobiological regulation.
In brief
Certain neurodiversity profiles may be associated with significant challenges in educational and family contexts. In light of the limitations that conventional strategies may sometimes present, our team rigorously investigates the potential of complex plant matrices documented in ethnobotanical and ethnopharmacological sources.
Extracts traditionally used in contexts related to childhood concentration difficulties are currently being evaluated under contemporary scientific criteria in order to assess their biological plausibility and regulatory profile.
The project
Our project focuses on the development of an innovative plant extract, primarily derived from Cistus albidus and complemented with other Mediterranean species such as rosemary (and Rosmarinus officinalis) and hawthorn (Crataegus monogyna), among others. This unique formula was discovered through an ethnobotanical study, and its efficacy has been confirmed and further explored through ethnopharmacological research.
Preliminary Results
Within the framework of preliminary ethnopharmacological evaluations, behavioral changes compatible with improved attentional and emotional regulation were observed in certain pediatric profiles presenting manifestations of hyperactivity. These observations are based on systematized descriptions within contexts of documented traditional use and should be interpreted with caution, as they are currently being examined through additional research using controlled methodologies.
From a phytochemical perspective, it is hypothesized that the potential synergistic interaction among polyphenols, terpenes, and other plant-derived compounds may contribute to the observed effects. However, this hypothesis requires rigorous experimental validation before any mechanistic conclusions can be drawn.
The potential
Preliminary data derived from our investigations suggest that the extract may interact with several biological processes described in the literature as relevant to profiles such as ADHD and co-occurring ASD+ADHD configurations. These include parameters related to mitochondrial function, gut–brain axis dynamics, neuroimmune regulation, and the modulation of monoaminergic systems.
These findings should be interpreted within an exploratory framework and require further validation through controlled and replicable studies.
The next level
The progression of this program toward a potential regulated development requires structured investment to complete the preclinical and clinical phases mandated by European regulatory frameworks, including evaluation under the procedures established by the European Medicines Agency (EMA).
Only through the generation of robust evidence regarding safety, quality, and therapeutic plausibility will it be possible to determine its potential for implementation within a formal regulatory framework.